SH0.F · Shionogi & Co., Ltd

-

Please sign in to comment on SH0.F

1 Comment

Admin

4 years, 5 months ago

Shionogi & Co., Ltd is currently in a long term uptrend where the price is trading 15.0% above its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.9.

Shionogi & Co., Ltd's total revenue sank by 18.0% to $76B since the same quarter in the previous year.

Its net income has dropped by 6.5% to $37B since the same quarter in the previous year.

Finally, its free cash flow fell by 53.2% to $5B since the same quarter in the previous year.

Based on the above factors, Shionogi & Co., Ltd gets an overall score of 2/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	F
CurrencyCode	EUR
ISIN	JP3347200002

Target Price	None
Dividend Yield	2.9%
Beta	0.12
Market Cap	13B
PE Ratio	12.41

ABOUT

Shionogi & Co., Ltd

Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

SH0.F · Shionogi & Co., Ltd

-

Shionogi & Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Shionogi & Co., Ltd using a moving average strategy